03429nam 2200577 a 450 991014454760332120211007214327.01-280-76855-X97866136793210-470-71901-X0-470-71648-7(CKB)1000000000687271(EBL)703747(OCoLC)775867244(SSID)ssj0000715146(PQKBManifestationID)11472746(PQKBTitleCode)TC0000715146(PQKBWorkID)10700296(PQKB)10932788(MiAaPQ)EBC703747(EXLCZ)99100000000068727119860103d1957 uy 0engur|n|---|||||txtccrCiba Foundation Symposium on the Chemistry and Biology of Purines[electronic resource] /editors for the Ciba Foundation, G.E.W. Wolstenholme and Cecilia M. O'ConnorBoston Little, Brown and Co.[1957]1 online resource (350 p.)Ciba Foundation symposiaDescription based upon print version of record.0-470-72244-4 Includes bibliographical references and indexes.CHEMISTRY AND BIOLOGY OF PURINES; CONTENTS; Opening remarks; Synthesis and properties of purines of potential biological interest; Discussion; Some synthetic studies on purines and related heterocycles; Discussion; Some new -N-methylpurines; The structure of the hydroxypurines investigated by O-and N-methylation; Discussion; The spectra and structure of the monohydroxypurines and other potentially tautomeric purines; Short Communication; The p-electron properties of purine calculated by the L.C.A.O. method; Discussion; The degradation of uric acid by water under pressureThe 8-position in purines. The chemical and biological transformation of purines into pteridines Discussion; Cvclonucleosides; Discussion; Stereochemistry of nucleoside synthesis; Discussion; Synthetic chemical investigations related to the metabolism of purines; Discussion; The effects of potential antipurines on a purine-requiring strain of Escherichla coli; Discussion; The chemistry of new purines in the B12 series of vitamins; Biological and microbiological activity of purine analogues of vitamin B12; Discussion; Puromycin; DiscussionChemical and biological behaviours of 9-b-D-ribofuranosylpurine Discussion; On the activation of the one-carbon unit for the biosynthesis of purine nucleotides; The enzymatic synthesis of inosinic acid de novo; Discussion; Enzymic control of purines by xanthine oxidase; Discussion; The biological effects of 8-azapurines; Discussion; Biochemical effects of 6-mercaptopurine; Discussion; The use of 6-mercaptopurine in the treatment of leukemia; Discussion; General Discussion; Chairman's closing remarksCiba Foundation symposium.PurinesCongressesElectronic books.Purines612.015Wolstenholme G. E. W(Gordon Ethelbert Ward)63039O'Connor Cecilia M(Cecilia Mary),1927-207754MiAaPQMiAaPQMiAaPQBOOK9910144547603321Ciba Foundation Symposium on the Chemistry and Biology of Purines2132668UNINA05470nam 22006375 450 991030035860332120250710061720.00-85729-910-710.1007/978-0-85729-910-9(CKB)3710000000078688(EBL)1592838(SSID)ssj0001090482(PQKBManifestationID)11657116(PQKBTitleCode)TC0001090482(PQKBWorkID)11020798(PQKB)10000289(MiAaPQ)EBC1592838(DE-He213)978-0-85729-910-9(PPN)176095535(EXLCZ)99371000000007868820131213d2014 u| 0engur|n|---|||||txtccrControversies in the Management of Gynecological Cancers /edited by Jonathan A. Ledermann, Carien L. Creutzberg, Michael A. Quinn1st ed. 2014.London :Springer London :Imprint: Springer,2014.1 online resource (347 p.)Description based upon print version of record.0-85729-909-3 Includes bibliographical references at the end of each chapters and index.1. Controversies in the Treatment of Women with Early Stage Epithelial Ovarian Cancer -- 2. Recurrent Ovarian Cancer: When to Treat and How to Assess -- 3. New Views of Ovarian Carcinoma Types: How will this Change Practice? -- 4. Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated -- 5. What is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer? -- 6. Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink? -- 7. Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries -- 8. What is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer? -- 9. Response as a Measure of Treatment Efficacy in Clinical Trials:  Should RECIST Be Abandoned? -- 10. What are the Treatment Options for Recurrent Ovarian Cancer? -- 11. How To Study Rare Gynaecological Tumours: Trials or Registries? -- 12. What is the Best Treatment Model for Gynaecological Cancers? Does Centralization Help? -- 13. When Should Surgery be Performed for the First-Line Treatment of Advanced Ovarian Cancer? -- 14. Does Intraperitoneal Therapy for Ovarian Cancer have a Future? -- 15. Maintenance Therapy for First-Line Treatment of Ovarian Cancer—Is this the Strategy for the Future? -- 16. What is the Value of Lymphadenectomy in Early Ovarian Cancer? -- 17. Sentinel Node Biopsy—Does it Help in the Management of Vulvar Cancer? -- 18. Controversies in the Management of Advanced Vulvar Cancer -- 19. Bowel Obstruction in Ovarian Cancer: To Operate or Not? -- 20. Early Cervical Cancer: Can Fertility be Safely Preserved? -- 21. What is the Role of PET/CT in Gynaecologic Cancers? -- 22. Do Intensity-Modulated Radiation, Image-Guided Radiation, and 3D Brachytherapy Significantly Advance Radiotherapeutic Management of Gynecologic Cancers? -- 23. What is the Place of Hormone Replacement Therapy in Ovarian, Endometrial, and Breast Cancer? -- 24. Familial Gynaecological Cancers: Whom to Screen and How to Manage? -- 25. TrialDesign: Should Randomized Phase III Trials in Gynaecological Cancers be Abandoned? -- 26. How Should Early Gestational Trophoblastic Disease be Managed? -- 27. Should Every Woman with Gynaecologic Cancer Undergo Routine Screening for Psychological Distress and Sexual Dysfunction? -- 28. How Should Gynaecological Sarcomas be Managed? -- 29. What is the Future of Immunotherapy in Ovarian Cancer?.Gynecological cancers are some of the most commonly occurring malignancies in women. Despite their high incidence, treatment and management of these cancers remain controversial, with conflicting evidence about  many aspects of the disease.   Controversies in the Management of Gynecological Cancers offers a unique assessment of the opposing sides of the controversial issues associated with gynecological cancers, and aims to provide professionals in the field with a keener sense of the underlying evidence-base and a starting point from which to follow the ongoing debate. A section on the direction of future research to resolve these issues completes the discussion in each chapter.   This book will appeal to specialists, trainees and healthcare workers in gynecological oncology, gynecologists, medical oncologists and radiation oncologists, and is an excellent starting point for anyone who wishes to gain a better understanding of the complex nature of the management of gynecological malignancy.  .OncologyGynecologyCancerTreatmentOncologyGynecologyCancer TherapyOncology.Gynecology.CancerTreatment.Oncology.Gynecology.Cancer Therapy.616.99465616.9946506Ledermann Jonathan Aedthttp://id.loc.gov/vocabulary/relators/edtCreutzberg Carien Ledthttp://id.loc.gov/vocabulary/relators/edtQuinn Michael Aedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910300358603321Controversies in the Management of Gynecological Cancers1522336UNINA